214 related articles for article (PubMed ID: 8055814)
21. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
[TBL] [Abstract][Full Text] [Related]
22. Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor.
Ezzat S; Ezrin C; Yamashita S; Melmed S
Cancer; 1993 Jan; 71(1):66-70. PubMed ID: 8416728
[TBL] [Abstract][Full Text] [Related]
23. Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.
Garcia MB; Koppeschaar HP; Lips CJ; Thijssen JH; Krenning EP
J Endocrinol Invest; 1994 Jan; 17(1):59-65. PubMed ID: 7911814
[TBL] [Abstract][Full Text] [Related]
24. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine.
Campino C; Szecowka J; Lopez JM; Seron-Ferre M
Clin Endocrinol (Oxf); 1995 Jul; 43(1):111-6. PubMed ID: 7641402
[TBL] [Abstract][Full Text] [Related]
25. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
[TBL] [Abstract][Full Text] [Related]
26. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.
Rau H; Althoff PH; Schmidt K; Usadel KH
Acta Endocrinol (Copenh); 1992 Mar; 126(3):247-52. PubMed ID: 1574954
[TBL] [Abstract][Full Text] [Related]
27. Plasma growth hormone and prolactin responses to TRH and arginine given before and during bromocriptine therapy to patients with acromegaly.
Hanew K; Sasaki A; Mouri T; Yoshinaga K
Acta Endocrinol (Copenh); 1980 Nov; 95(3):298-307. PubMed ID: 6776756
[No Abstract] [Full Text] [Related]
28. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin.
Werner S; Hall K; Sjöberg HE
Acta Endocrinol Suppl (Copenh); 1978; 216():199-206. PubMed ID: 347862
[TBL] [Abstract][Full Text] [Related]
29. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
30. The influence of bromocriptine on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly.
Roelfsema F; Goslings BM; Frölich M; Moolenaar AJ; Seters AP; Van Slooten H
Clin Endocrinol (Oxf); 1979; 11(2):235-44. PubMed ID: 114344
[TBL] [Abstract][Full Text] [Related]
31. Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly.
Giustina A; Doga M; Bussi AR; Licini M; Schettino M
Acta Endocrinol (Copenh); 1993 Feb; 128(2):131-5. PubMed ID: 7680832
[TBL] [Abstract][Full Text] [Related]
32. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly.
Wagenaar AH; Harris AG; van der Lely AJ; Lamberts SW
Acta Endocrinol (Copenh); 1991 Dec; 125(6):637-42. PubMed ID: 1789059
[TBL] [Abstract][Full Text] [Related]
33. Induction of growth hormone and prolactin secretion by luteinizing hormone-releasing hormone and its blockade by bromoergocriptine in acromegalic patients.
Ishibashi M; Yamaji T; Kosaka K
J Clin Endocrinol Metab; 1978 Aug; 47(2):418-21. PubMed ID: 400720
[TBL] [Abstract][Full Text] [Related]
34. Gsp mutation in acromegaly and its influence on TRH-induced paradoxical GH response.
Goto Y; Kinoshita M; Oshino S; Arita H; Kitamura T; Otsuki M; Shimomura I; Yoshimine T; Saitoh Y
Clin Endocrinol (Oxf); 2014 May; 80(5):714-9. PubMed ID: 24111551
[TBL] [Abstract][Full Text] [Related]
35. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
36. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly.
Hanew K; Sugawara A; Shimizu Y; Sato S; Sasaki A; Tazawa S; Ishii K; Saitoh T; Saso S; Yoshinaga K
Endocrinol Jpn; 1989 Jun; 36(3):429-38. PubMed ID: 2510991
[TBL] [Abstract][Full Text] [Related]
37. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months.
Schwinn G; Dirks H; McIntosh C; Köbberling J
Eur J Clin Invest; 1977 Apr; 7(2):101-7. PubMed ID: 404154
[TBL] [Abstract][Full Text] [Related]
38. Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas.
Fanghanel G; Larraza O; Villalobos M; Fanghanel L; Velasco M; Velasco F
Can J Neurol Sci; 1990 Feb; 17(1):78-82. PubMed ID: 2107017
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states.
Verde G; Chiodini PG; Liuzzi A; Cozzi R; Favales F; Botalla L; Spelta B; Dalla Bonzana D; Rainer E; Horowski R
J Endocrinol Invest; 1980; 3(4):405-14. PubMed ID: 6782153
[TBL] [Abstract][Full Text] [Related]
40. Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995--bromocriptine combined treatment results.
Cremonini N; Graziano E; Chiarini V; Sforza A; Zampa GA
J Clin Endocrinol Metab; 1992 Oct; 75(4):1166-9. PubMed ID: 1400888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
